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Abstract
Objectives To assess the association between pre-diabetes and risk
of stroke, and to evaluate whether this relation varies by diagnostic
criteria for pre-diabetes.
Design Systematic review and meta-analysis of prospective studies.
Data sources A search of Medline, Embase, and the Cochrane Library
(1947 to 16 July 2011) was supplemented by manual searches of
bibliographies of key retrieved articles and relevant reviews.
Selection criteria Prospective cohort studies that reported multivariate
adjusted relative risks and corresponding 95% confidence intervals for
stroke with respect to baseline pre-diabetes were included.
Data extraction Two independent reviewers extracted data on
pre-diabetes status at baseline, risk estimates of stroke, study quality,
and methods used to assess pre-diabetes and stroke. Relative risks
were pooled using random effects models when appropriate. Associations
were tested in subgroups representing different characteristics of
participants and studies. Publication bias was evaluated with funnel
plots.
Results The search yielded 15 prospective cohort studies including 760
925 participants. In 8 studies analysing pre-diabetes defined as fasting
glucose 100-125 mg/dL (5.6-6.9 mmol/L), the random effects summary
estimate did not show an increased risk of stroke after adjustment for
established cardiovascular risk factors (1.08, 95% confidence interval
0.94 to 1.23; P=0.26). In 5 studies analysing pre-diabetes defined as
fasting glucose 110-125 mg/dL (6.1-6.9 mmol/L), the random effects
summary estimate showed an increased risk of stroke after adjustment
for established cardiovascular risk factors (1.21, 1.02 to 1.44; P=0.03).
In 8 studies with information about impaired glucose tolerance or
combined impaired glucose tolerance and impaired fasting glucose, the
random effects summary estimate showed an increased risk of stroke
after adjustment for established cardiovascular risk factors (1.26, 1.10
to 1.43; P<0.001). When studies that might have enrolled patients with
undiagnosed diabetes were excluded, only impaired glucose tolerance
or a combination of impaired fasting glucose and impaired glucose
tolerance independently raised the future risk of stroke (1.20, 1.07 to
1.35; P=0.002).
Conclusion Pre-diabetes, defined as impaired glucose tolerance or a
combination of impaired fasting glucose and impaired glucose tolerance,
may be associated with a higher future risk of stroke, but the relative
risks are modest and may reflect underlying confounding.
Introduction
The growing obesity epidemic in the United States has been
inextricably linked with a surge in rates of pre-diabetes.
1
Pre-diabetes has been called “America’s largest healthcare
epidemic,”
1 and current estimates indicate that about 35% of
adults in the United States have pre-diabetes, or approximately
79 million people. This number is more than three times the
numberofpeoplewithfrankdiabetes(26millionpeople).
2Also
concerning is that the overwhelming majority of people with
pre-diabetes may be unaware of their risk of diabetes.
3
Pre-diabetes is generally defined as impaired fasting glucose,
impaired glucose tolerance, or both.
4 In 1997 the American
Diabetes Association defined impaired fasting glucose as a
plasma glucose concentration of 110 to 125 mg/dL (6.1-6.9
mmol/L).
5However,in2003theAmericanDiabetesAssociation
redefined impaired fasting glucose as a plasma concentration
of 100 to 125 mg/dL (5.6-6.9 mmol/L).
6 The underlying
pathophysiologicaldisturbances(insulinresistanceandimpaired
β cell function) responsible for the development of type 2
diabetesareexpressedinpeoplewithpre-diabetes.
7Peoplewith
pre-diabetes harbour the same vascular risk factors
(dysglycaemia, hypertension, dyslipidaemia, obesity, physical
inactivity, insulin resistance, endothelial dysfunction,
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Research
RESEARCHpro-coagulant state, and inflammation) that place people with
type 2 diabetes at high risk of macrovascular complications.
7
Pre-diabetes has been linked to a modest increase in overall
cardiovascular events,
8 but the effect of pre-diabetes on risk of
future stroke has not been established.
The objective of this study was twofold: to investigate the
directionandmagnitudeoftherelationofpre-diabeteswithrisk
of future stroke after accounting for other stroke risk factors,
and to evaluate whether this relation varies on the basis of the
threshold for impaired fasting glucose or inclusion of impaired
glucose tolerance criteria in the diagnosis of pre-diabetes.
Methods
The search strategy was in accordance with the
recommendationsoftheMeta-analysisofObservationalStudies
inEpidemiology(MOOSE)Group.
9WesearchedPubMed(1947
to 16 July 2011), Embase (1947 to 16 July 2011), and the
CochraneLibrary(1947to16July2011),usingthesearchterms
“prediabetes”or“impairedfastingglucose”or“impairedglucose
intolerance” or “borderline diabetes” AND “cardiovascular
disease” or “myocardial ischemia” or “myocardial infarct” or
“ischemic heart disease” or “coronary heart disease” or
“coronary artery disease” or “angina” or “stroke” or
“cerebrovascular disease” or “cerebrovascular attack” or
“cerebral ischemia” or “brain ischemia” or “intracranial
hemorrhage”AND“cohort”or“observational”or“prospective”
or “trial.” We restricted the search to studies in humans and
applied no language restrictions. We retrieved further
information by a manual search of references from recent
reviews and relevant published original studies.
Inclusion and exclusion criteria
We selected studies if they met the following entry criteria:
prospectively collected data within cohort studies or clinical
trials;bloodglucoseevaluatedatbaseline;assessedstrokeevent
as an endpoint during the follow-up period (for example, if a
person had a stroke before enrolment, the stroke event during
follow-up would be recurrent stroke; if a person did not have a
stroke before enrolment, the stroke event during follow-up
would be the first stroke event); intended follow-up of at least
oneyearforallparticipants;andreportedquantitativeestimates
of the multivariate adjusted (that is, age, sex, and one other
conventional vascular risk factor as minimum requirements)
relative risk and 95% confidence interval or standard error for
the log relative risk for future stroke associated with baseline
pre-diabetes. Pre-diabetes was defined as impaired fasting
glucose (fasting glucose 100-125 mg/dL or 110-125 mg/dL
5 6)
or impaired glucose tolerance (two hour values in the oral
glucose tolerance test of 140-199 mg/dL (7.8-11.0 mmol/L)).
4
The reference group (that is, normoglycaemia) included people
with fasting glucose less than 100 mg/dL, fasting glucose less
than 110 mg/dL, or non-fasting glucose less than 140 mg/dL.
Although we preferred studies that measured baseline fasting
plasma glucose and oral glucose tolerance test, in the main
analysiswedidnotexcludestudiesthatmeasuredonlybaseline
fasting or non-fasting glucose concentrations. So, for instance,
people with a fasting plasma glucose of 126 mg/dL or greater
(thatis,diabetesmellitus)mayhaveinadvertentlybeenincluded
if only non-fasting glucose was measured; on the other hand,
people with a non-fasting glucose of 200 mg/dL or greater (that
is, diabetes mellitus) might have been included if a study
measuredonlyfastingglucose.Wealsodidasensitivityanalysis
that excluded studies that might have inadvertently enrolled
peoplewhometthecriterionforadiagnosisofdiabetes.Finally,
wealsoexcludedstudiesinwhichmorethan50%ofparticipants
were pregnant women.
Data extraction and quality assessment
Twoinvestigators(MLandKSH)independentlyabstracteddata
fromeligiblestudies.Discrepancieswereresolvedbydiscussion
with a third investigator (BO) and by referencing the original
report. Relevant data included the first author’s name, study
name, year of publication, country of origin, number of
participants, age of participants, duration of follow-up,
percentage of participants followed to the end of a study,
outcome assessment, prevalence of pre-diabetes, multivariate
adjusted relative risks or hazard ratios for stroke and
corresponding95%confidenceinterval,andcovariatesadjusted
for in the statistical analysis.
Weassessedstudies’qualityonthebasisofadequateadjustment
forpotentialconfounders(atleastsixofsevenfactors:age,sex,
hypertensionorsystolicbloodpressureorantihypertensivedrug,
body mass index or other measure of overweight/obesity,
physical activity, cholesterol concentration or statin use, and
smoking).
Statistical analysis
We used multivariate adjusted outcome data for our data
analysis. We converted these values in every study by using
their natural logarithms and calculated the standard errors from
these logarithmic numbers and their corresponding 95%
confidence intervals. The statistical analysis used the inverse
variance approach to combine log relative risks and standard
errors. We used a random effect model and assessed
heterogeneity by P value of τ
2 statistics.
10 We used a funnel plot
based on the primary outcome to evaluate potential systematic
biasinstudies,includingpublicationbias.AllreportedPvalues
were two sided with significance set at less than 0.05.
We calculated summary estimates of relative risk for fasting
glucose of 100 to 125 mg/dl, fasting glucose of 110 to 125
mg/dL, and presence of impaired glucose tolerance with or
without impaired fasting glucose. We did predefined subgroup
analysesaccordingtopopulationtype(generalpopulationversus
established cardiovascular disease at entry), ethnicity (Asians
versus non-Asians), sex (men versus women versus both men
and women), mean age at entry (<65 years versus ≥65 years),
possibility of enrolling patients with diabetes (none enrolled
versus might be enrolled), and adjustment for confounders
(adequate adjustment versus inadequate adjustment). We used
theCochraneCollaboration’sReviewManagersoftwarepackage
(RevMan 5) for the meta-analysis of observational studies.
11 12
Results
The literature review identified 62 full articles for detailed
assessment. We excluded 29 studies owing to lack of a
multivariateadjustedstrokeestimate,sevenstudiesforproviding
only fatal endpoints; two studies for follow-up duration less
than one year; eight studies for lacking proper impaired fasting
glucoseorimpairedglucosetolerancecategoriesatbaseline;
13-20
andonestudythatwasretrospectiveratherthanprospective(fig
1⇓). The final analysis included 760 925 participants from 15
prospectivecohortstudies.
21-35Allstudiesexcludedpeoplewith
fasting glucose of 126 mg/dL or greater, except one study in
which only non-fasting glucose was measured at baseline.
33 In
thisstudy,impairedglucosetolerancewasdefinedasnon-fasting
venous plasma glucose 140 to 199 mg/dL, and a non-fasting
glucosebelow140mg/dLwasusedasareference;afewpatients
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RESEARCHwith fasting glucose of 126 mg/dL or greater might thus have
been enrolled in the impaired glucose tolerance group or
referencegroup.
33Ontheotherhand,among15includedstudies,
seven studies measured only fasting glucose at
baseline
24 25 27 29 31 32 34; so some people with non-fasting glucose
of200mg/dLorgreatermighthavebeincludedinthesestudies.
Table 1⇓ shows the characteristics of the studies. Among the
15 studies, nine were derived from the general population, one
from the aged population, four from populations with a history
of coronary artery disease, and one from a population with
history of stroke or transient ischemic attack. Ten studies
reported any stroke as an endpoint, four reported ischaemic
stroke as an endpoint, and one reported ischaemic and
haemorrhagic strokes separately as endpoints. Sample sizes
ranged from 1032 to 652 901, and follow-up durations ranged
fromoneyearto17years.Onestudyenrolledonlywomen,and
another enrolled only men; the remainder enrolled both men
and women.
In eight studies with information about fasting glucose 100 to
125 mg/dL, the random effects summary estimate did not show
increased risk of stroke after adjustment for established
cardiovascular risk factors (relative risk 1.08, 95% confidence
interval 0.94 to 1.23; P=0.26) (fig 2⇓). We found evidence of
heterogeneity across studies (P for heterogeneity <0.0001) but
no major asymmetrical appearance in the funnel plot
(supplementary fig A).
In five studies with information about fasting glucose 110 to
125 mg/dL, the random effects summary estimate showed an
increased risk of stroke after adjustment for established
cardiovascular risk factors (relative risk 1.21, 1.02 to 1.44;
P=0.03) (fig 3⇓). Although we again found evidence of
heterogeneity across studies (P for heterogeneity 0.003), we
saw no substantial asymmetrical appearance in the funnel plot
(supplementary fig B).
Eightstudieshadinformationaboutimpairedglucosetolerance
orcombinationofimpairedfastingglucoseandimpairedglucose
tolerance. The random effects summary estimate for these
studies showed an increased risk of stroke after adjustment for
established cardiovascular risk factors (relative risk 1.26, 1.10
to 1.43; P<0.001) (fig 4⇓). We found no obvious heterogeneity
across studies (P=0.15) and no major asymmetric appearance
in the funnel plot (supplementary fig C).
In a sensitivity analysis excluding the study that might have
enrolled people with fasting glucose of 126 mg/dL or above,
33
wesawasmaller,butstillsignificant,effectofimpairedglucose
tolerance or combination of impaired fasting glucose and
impaired glucose tolerance on future stroke (relative risk 1.20,
1.07 to 1.35; P=0.002). However, when we excluded studies
thatmighthaveenrolledpeoplewithnon-fastingglucoseof200
mg/dL or above, neither fasting glucose 100 to 125 mg/dL nor
110 to 125 mg/dL was significantly associated with increased
risk of future stroke (relative risks 0.91, 0.50 to 1.63, and 1.11,
0.77 to 1.61) (table 2⇓).
Table 2⇓ shows subgroup analyses. Heterogeneity existed
between estimates among participants’ ages at entry (<65 years
versus ≥65 years) and degree of adjustment for confounders
(adequate adjustment versus inadequate adjustment). In four
studies with adequate adjustment of confounders, baseline
impaired glucose tolerance or combination of impaired fasting
glucose and impaired glucose tolerance was associated with a
trend towards higher future risk of stroke (relative risk 1.11,
0.99 to 1.25; P=0.08). We further analysed three studies that
provided information on participants with fasting glucose of
100 to 109 mg/dL and found no associated increased risk of
stroke (relative risk 0.94, 0.73 to 1.20; P=0.61).
Discussion
In this meta-analysis of 15 prospective studies, with more than
760 000 participants, we found that people with baseline
pre-diabetes, defined as impaired fasting glucose of 110 to 125
mg/dL (6.1-6.9 mmol/L) or presence of impaired glucose
tolerance, were at modestly higher risk of future stroke. The
AmericanDiabetesAssociation’scurrent,lessstringentimpaired
fasting glucose definition (fasting glucose 100-125 mg/dL
(5.6-6.9 mmol/L)) of pre-diabetes was not associated with
increased risk of stroke. After further exclusion of studies that
mayhaveenrolledpatientswithdiabetes,onlyimpairedglucose
tolerance or a combination of impaired fasting glucose and
impairedglucosetoleranceshowedsignificantrelationwithrisk
of stroke. The observed lack of a relation between impaired
fasting glucose and risk of future stroke is in accord with results
from a recent individual level collaborative meta-analysis.
36 It
reinforces the notion that two hour postprandial glucose
challenge is probably a stronger predictor of macrovascular
complications than is fasting glucose.
37
The risk of stroke seems to rise progressively across the
spectrum of insulin resistance from impaired fasting glucose to
impaired glucose tolerance to diabetes,
37 suggesting that
hyperglycaemia might be a continuous risk factor for stroke.
Nonetheless,peoplewithpre-diabetescanbeasinsulinresistant
as people with diabetes.
38 A common mechanism linking all
components of the insulin resistance syndrome is the
cellular/molecular cause of the insulin resistance,
38 39 which not
only promotes atherogenesis and inflammation but also leads
to or aggravates other components of the syndrome, which
themselves are major vascular risk factors. Also, people with
pre-diabetes develop dyslipidaemia characterised by small,
dense, atherogenic low density lipoprotein particles,
hypertriglyceridaemia, and reduced high density lipoprotein
cholesterol,
40 41 as well as accelerated atherogenesis.
42
All of the aforementioned notwithstanding, the relation of
pre-diabetes with risk of future stroke was relatively modest,
sounderlyingconfoundingisprobablyeasilyabletoaffectthese
results.Furthermore,comparedwiththestudieswithinadequate
adjustment of confounders, the effect size of the association of
pre-diabetes with stroke risk was attenuated in those studies
that used adequate adjustment.
We found that the definition of pre-diabetes seems to matter
with regard to risk of stroke. Even though insulin resistance
may be a condition on a continuous scale, when it comes to
stroke, the only diagnostic approach for pre-diabetes that is
clearly linked to risk seems to be one that includes impairment
inglucosetolerance.Ofnote,theAmericanDiabetesAssociation
recentlyupdateditsscreeningrecommendationforpre-diabetes
toincludehaemoglobinA1casanotherdiagnostictestingoption.
4
TheserecommendationsstatethatanhaemoglobinA1cbetween
5.7% and 6.4% identifies people at high risk of diabetes and
thatthelabelofpre-diabetescanbeapplied.
4Wedidnotinclude
haemoglobin A1c criteria in the investigation of the association
between pre-diabetes and risk of stroke because this recent
diagnostic criterion had not yet been proposed when the
prospective cohort studies we evaluated were conducted.
Ongoing or future prospective cohort studies that include
haemoglobin A1c among their baseline variables may provide
more information on the association between pre-diabetes and
risk of stroke.
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RESEARCHStrengths and limitations of study
Our study has several limitations. Firstly, a large amount of
heterogeneitywasobservedintheresultsofthevariousstudies.
Although we did subgroup analyses, heterogeneity persisted in
many subgroups, suggesting that other factors might explain
some results. Despite these limitations, the results of this
systematic review are possibly the most precise estimate
available of the nature and strength of the relation between
pre-diabetes and future risk of stroke. Secondly, knowing
whether strokes occurred before or after diagnosis of diabetes
during the study period would have been helpful. Such
information might have clarified to what degree pre-diabetes
itself is a risk factor or whether it simply reflects the risk
associated with development of overt diabetes. Thirdly, 85%
of the patients in the 15 included studies were enrolled in one
study(whichenrolledonlyKoreanmen).
31However,theweight
of this study was actually only 17% in the analysis of fasting
glucose 100 to 125 mg/dL and 27% in the analysis of fasting
glucose 110 to 125 mg/dL. Fourthly, although most studies
included in this meta-analysis used all stroke as an endpoint, a
few evaluated only ischaemic stroke as an endpoint. Fifthly,
somepeoplewithdiabetesmellitusatbaselinemighthavebeen
included in our analyses owing to the design of some studies in
which only fasting or non-fasting glucose was measured, and
determining the exact percentage of such patients in the
pre-diabetes and reference groups was difficult. However, we
still found a modest but increased risk of future stroke among
people with impaired glucose tolerance or a combination of
impaired fasting glucose and impaired glucose tolerance when
we excluded studies that may have enrolled patients with
diabetes.
Conclusions and policy implications
An immediate implication of our findings is that people with
pre-diabetes should be aware that they are at increased risk of
future stroke. Also, pre-diabetes is not only a risk factor for
strokebutisalsofrequentlyassociatedwiththepresenceofone
or more other recognised major cardiovascular risk factors.
7
When pre-diabetes is discovered, the person’s overall
cardiovascular risk factor profile should be reviewed to ensure
that risk factors are being appropriately modified. Given the
strong relation between being overweight/obese and
pre-diabetes,recommendingthemaintenanceofanidealweight
may improve clinical outcomes in these patients. For people
with pre-diabetes, weight loss in conjunction with healthy
lifestyle changes is associated with decreased risk of
transitioningtofrankdiabetesandmayevenreducefuturestroke
events.
43 44 Our study also underscored a need to evaluate both
fasting glucose and two hour postprandial glucose challenge
for identifying people with pre-diabetes who may be at risk of
stroke.Finally,randomisedcontrolledtrialsevaluatingtheeffect
of glycaemic control on the occurrence of stroke among people
with impaired glucose tolerance or a combination of impaired
fasting glucose and impaired glucose tolerance are warranted.
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RESEARCHWhat is already known on this topic
Pre-diabetes is a surging epidemic in many developed countries
Pre-diabetes has been linked to a modest rise in overall cardiovascular risk, but the effect of pre-diabetes on risk of future strokes has
not been established
The definition of pre-diabetes includes presence of impaired fasting glucose, impaired glucose tolerance, or both
What this study adds
People with pre-diabetes on the basis of presence of impaired glucose tolerance had an independent risk of future stroke that was 20%
greater than those with a normal glycaemia
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not linked to future stroke risk
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RESEARCHTables
Table 1| Characteristics of included studies
Adjustment
for
confounders†
Adjustment
variables
Endpoint
assessed
during
follow-up
Baseline
pre-diabetes
categoryand
definition
Prevalence
of
pre-diabetes
Years of
follow-up in
all
participants
Average
age
(range
or SD)
Sample
size of
cohorts
(%
women)
Population
characteristics* Country
Study and
publication
year
(% followed
up to or
died before
stated time
point)
Adequate Age, sex, SBP,
ECG abnormalities,
BMI, total and HDL
cholesterol, smoking
habits, alcohol
intake, and regular
exercise
Ischaemic
stroke
IFG 100 , IFG
110, IGT
NA 14 (100%) 58 (10) 2421
(57%)
General,
excluded history
of CVD
(excluded all
diabetes)
Japan Doi 2010
21
Adequate Age, sex, centre,
MAP, BMI, total
cholesterol, and
smoking status
All stroke IFG 110, IGT 22% 12.9 (not
reported)
55
(20-90)
18 360
(54%)
General
(excluded all
diabetes)
Finland,
Sweden
Hyvärinen
2009
22
Adequate Age, sex,
community,
hypertension status,
BMI, TSF, SSF,
total and HDL
cholesterol, smoking
Ischaemic
stroke
IFG 110, IGT 7% 17 (not
reported)
53
(40-69)
10 582
(59%)
General,
excluded history
of CVD
(excluded all
diabetes)
Japan Iso 2004
23
status, alcohol
intake, and (for
women)
menopausal status
Adequate Age, sex, obesity,
hypertension,
physical activity,
total cholesterol,
triglycerides, apo
B:apo A ratio, Q
All stroke IFG 100 22% 8 (not
reported)
59
(45-70)
1167
(30%)
CAD (might
include
non-fasting
glucose ≥200
mg/dL)
Sweden Janszky
2009
24
wave infarction, and
education
Not adequate Sex, previous stroke
or TIA, atrial
fibrillation, history of
MI, HF, poorly
controlled
hypertension (SBP
Ischaemic
stroke
IGT 12% 9.6 (not
reported)
70 1032
(52%)
70-year-old
people (excluded
all diabetes)
Finland Kaarisalo
2006
26
≥160 mm Hg or
DBP ≥95 mm Hg),
current smoking,
acetylsalicylic acid
use,normalmemory
Adequate Age, current
smoking, physical
activity, alcoholic
drinks/week, BMI,
overall health
status, use of
All stroke and
transient
ischaemic
attack
IFG 100 25% 6.8 (93.7%) 67
(44-79)
2763
(100%)
Postmenopausal
women with CAD
(might include
non-fasting
glucose ≥200
mg/dL)
USA Kanaya
2005
25
statins, diuretics,
ACEI and hormone
therapy, assignment
time dependent
covariates, race or
ethnicity, education,
previous PTCA,
previous CABG,
sign of HF, and >1
previous MI, using
baseline covariates;
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RESEARCHTable 1 (continued)
Adjustment
for
confounders†
Adjustment
variables
Endpoint
assessed
during
follow-up
Baseline
pre-diabetes
categoryand
definition
Prevalence
of
pre-diabetes
Years of
follow-up in
all
participants
(% followed
up to or
died before
stated time
point)
Average
age
(range
or SD)
Sample
size of
cohorts
(%
women)
Population
characteristics* Country
Study and
publication
year
stratified by clinical
centre
Not adequate Age, sex, BMI,
hypertension,
hyperlipidaemia,
and smoking and
drinking status
All stroke IFG 100 28% 11.7 (100%) 55
(30-79)
5321
(53%)
General,
excluded history
of CVD (might
include
non-fasting
glucose ≥200
mg/dL)
Japan Kokubo
2010
27
Not adequate Age, sex, history of
MI, HF, PVD,
stroke,
hyperlipidaemia,
diagnosis at
admission, and
All stroke IFG 110, IGT 24% 1 (not
reported)
65 (11) 4676
(70%)
CAD (excluded
all diabetes)
Europe Lezen
2006
28
treatment with
anti-thrombotic
drugs, lipid lowering
drugs, and β
blockers
Not adequate Age, sex, smoking,
CVD family history,
and elevated total
cholesterol
Ischaemic
and
haemorrhagic
stroke
separately
IFG 100 21% 10 (94%) 47
(35-64)
30 378
(47%)
General,
excluded history
of CVD (might
include
non-fasting
glucose ≥200
mg/dL)
China Liu 2007
29
Not adequate Age, sex,
hypertension
All stroke IGT 15% 9.7 (not
reported)
57 (> 35) 2938
(56%)
General,
excluded history
of stroke
Japan Oizumi
2008
30
Adequate Age, height,
smoking, alcohol
consumption,
regular exercise,
level of monthly
salary, area of
All stroke IFG 100, IFG
110
13% 8.8 (not
reported)
43
(30-64)
652 901
(0%)
General, men
(might include
non-fasting
glucose ≥200
mg/dL)
Korea Sung 2009
31
residence, BP, total
cholesterol, BMI
Adequate Age, sex, BMI,
hypertension,
triglycerides, %
HDL, and use of
antiplatelets or
antihypertensives.
Ischaemic
stroke and
TIA
IFG 100, IFG
110
30% 7 (not
reported)
60
(45-74)
13 999
(34%)
CAD (might
include
non-fasting
glucose ≥200
mg/dL)
Israel Tanne
2004
32
Not adequate Age, sex, smoking,
hypertension, and
minor ischaemic
stroke in history
All stroke IGT 5% 2.6 (not
reported)
65 (10) 3127
(35%)
TIA or minor
stroke (might
include fasting
glucose ≥126
mg/dL)
Netherlands Vermeer
2006
33
Adequate Age, sex,
race/ethnicity, SBP,
BMI, cigarette
smoking, total
cholesterol,
HDL-cholesterol,
All stroke IFG 100 14% 7.5 (not
reported)
62
(45-84)
6753
(47%)
General,
excluded history
of CVD (might
include
non-fasting
glucose ≥200
mg/dL)
USA Yeboah
2011
34
triglycerides, blood
pressure drug use,
and statin use
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RESEARCHTable 1 (continued)
Adjustment
for
confounders†
Adjustment
variables
Endpoint
assessed
during
follow-up
Baseline
pre-diabetes
categoryand
definition
Prevalence
of
pre-diabetes
Years of
follow-up in
all
participants
(% followed
up to or
died before
stated time
point)
Average
age
(range
or SD)
Sample
size of
cohorts
(%
women)
Population
characteristics* Country
Study and
publication
year
Adequate Age, sex, SBP,
DBP, BMI, waist
All stroke IFG 110 or
IGT
NA 13.4 (99.8%) 60
(45-74)
4507
(56%)
American
Indians, excluded
USA Zhang
2008
35
circumference, LDL history of stroke
and HDL (excluded all
diabetes) cholesterol,
triglycerides,
physical activity,
smoking, alcohol
use,
microalbuminuria,
and
macroalbuminuria
ACEI=angiotensin converting enzyme inhibitor; BP=blood pressure; BMI=body mass index; CABG=coronary artery bypass graft; CAD=coronary artery disease;
CVD=cardiovascular disease; DBP=diastolic blood pressure; ECG=electrocardiogram; HDL=high density lipoprotein; HF=heart failure; IFG 100=impaired fasting
glucose (fasting glucose 100-125 mg/dL); IFG 110=impaired fasting glucose (fasting glucose 110-125 mg/dL); IGT=impaired glucose tolerance (post-challenge
glucose 140-199 mg/dL); MAP=mean arterial pressure; MI=myocardial infarction; NA=not available; PTCA=percutaneous transluminal coronary angiography;
PVD=peripheral vascular disease; SBP=systolic blood pressure; SSF=subscapular skinfold thickness; TIA=transient ischaemic attack; TSF=triceps skinfold
thickness.
*Including whether patients with diabetes may have been included because only fasting or non-fasting glucose was measured.
†Adequate adjustment denoted adjustment of at least six of seven factors: age, sex, hypertension or systolic blood pressure or antihypertensive drug, body mass
index or other measure of overweight/obesity, physical activity, cholesterol concentration or statin use, and smoking.
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RESEARCHTable 2| Subgroup analyses
IGT or combination of IFG/IGT Fasting glucose 110-125 mg/dL Fasting glucose 100-125 mg/dL
Subgroups P value* RR (95% CI)
No of
studies P value* RR (95% CI)
No of
studies P value* RR (95% CI)
No of
studies
0.01 0.59 0.63 Population:
1.18 (1.06 to 1.31) 6 1.15 (0.99 to 1.33) 3 1.05 (0.91 to 1.21) 5 Without CVD history
at entry
1.77 (1.30 to 2.40) 2 1.36 (0.75 to 2.47) 2 1.17 (0.77 to 1.76) 3 With CVD history at
entry
0.98 0.60 0.92 Ethnicity:
1.24 (0.99 to 1.55) 4 1.08 (0.77 to 1.52) 2 1.07 (0.93 to 1.24) 4 Asians
1.23 (1.06 to 1.44) 4 1.21 (0.94 to 1.55) 3 1.09 (0.77 to 1.55) 4 Non-Asians
0.09 0.44 0.21 Sex:
0.95 (0.72 to 1.27) 2 0.94 (0.57 to 1.55) 1 0.91 (0.67 to 1.24) 3 Male
1.16 (0.86 to 1.56) 2 1.22 (0.78 to 1.90) 1 1.09 (0.79 to 1.49) 3 Female
1.37 (1.16 to 1.62) 6 1.45 (0.94 to 2.24) 2 1.25 (1.04 to 1.51) 4 Both
0.007 — 0.02 Mean age at entry:
1.15 (1.03 to 1.29) 5 1.21 (1.02 to 1.44) 5 1.12 (0.98 to 1.28) 7 <65 years
1.65 (1.30 to 2.08) 3 — 0 0.82 (0.65 to 1.03) 1 ≥65 years
0.05 0.58 0.47 Possibility of enrolling
patients with diabetes:
1.20 (1.07 to 1.35) 7 1.11 (0.77 to 1.61) 2 0.91 (0.50 to 1.63) 1 None enrolled
1.80 (1.23 to 2.63) 1 1.27 (0.95 to 1.72) 3 1.13 (0.99 to 1.29) 7 Might be enrolled
0.001 — 0.25 Adjustment for
confounders:
1.11 (0.99 to 1.25) 4 1.21 (1.02 to 1.44) 5 1.04 (0.87 to 1.25) 6 Adequate
1.60 (1.32 to 1.93) 4 — 0 1.19 (1.05 to 1.36) 2 Inadequate
CVD=cardiovascular disease; IFG=impaired fasting glucose; IGT=impaired glucose tolerance; RR=relative risk.
*For heterogeneity among subgroups.
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RESEARCHFigures
Fig 1 Study selection
Fig 2 Baseline fasting glucose 100-125 mg/dL versus risk of stroke
Fig 3 Baseline fasting glucose 110-125 mg/dL versus risk of stroke
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RESEARCHFig 4 Baseline impaired glucose tolerance (IGT) or combination of IGT and impaired fasting glucose versus risk of stroke
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